Compare Summit Therapeutics Inc (SMMT) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Western Alliance Bancorporation — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.07% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WAL | |
|---|---|---|
Market Cap | $10.48B | $8.84B |
Sector | Health | Financials |
52-Week High | $29.32 | $96.08 |
52-Week Low | $13.05 | $66.70 |
Enterprise Value | $9.90B | — |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.43 and net income margin of 25.63%, supported by consistent quarterly earnings outperformance. Recent news highlights Q2 2026 earnings miss but positive corporate recognition and leadership appointments.
Outlook remains positive with analyst consensus price target of $90.67 suggesting 12% upside. Risks include negative operating cash flow and high interest expenses. The bullish analyst sentiment (79% buy ratings) contrasts with technical bearishness, indicating potential value opportunity if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
